May 19, the meeting of phaseI clinical trial study of recombinant human erythropoietin (Fc) fusion proteininjection (hereinafter, rhEPO-Fc project) was held in Guangdong Provincial People’sHospital. The convening of the meeting marked the formal entry of the rhEPO-Fc project into the phase I. rhEPO-Fc isan innovative class I therapeutic biological product developed by DongguanTaili Bioengineering Co., Ltd. Boji Pharmaceutical provided the CRO service forits phase I clinical trial.